Jazz Pharmaceuticals is an international biopharmaceutical company, focused on identifying, developing and commercializing products for neurology and psychiatry. The Company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning.

Type
Public
HQ
Ballsbridge, IE
Founded
2003
Size (employees)
857 (est)+23%
Jazz Pharmaceuticals was founded in 2003 and is headquartered in Ballsbridge, IE
Report incorrect company information

Key People/Management at Jazz Pharmaceuticals

Bruce C. Cozadd

Bruce C. Cozadd

Chairman and Chief Executive Officer
Heather McGaughey

Heather McGaughey

Senior Vice President, Human Resources
Fintan Keegan

Fintan Keegan

Executive Vice President, Technical Operations
Russell J. Cox

Russell J. Cox

Executive Vice President and Chief Commercial Officer
Iain McGill

Iain McGill

Head of EUSA International and SVP, Jazz Pharmaceuticals

Jazz Pharmaceuticals Office Locations

Jazz Pharmaceuticals has offices in Palo Alto, Ballsbridge, Philadelphia and Oxford
Ballsbridge, IE (HQ)
Connaught House Burlington Rd
Oxford, GB
Oxford Business Park
Palo Alto, US
3180 Porter Drive
Philadelphia, US
2350 1818 Market St
Show all (4)
Report incorrect company information

Jazz Pharmaceuticals Financials and Metrics

Jazz Pharmaceuticals Financials

Jazz Pharmaceuticals's revenue was reported to be $1.62 b in FY, 2017
USD

Revenue (FY, 2017)

1.6 b

Gross profit (FY, 2017)

1.5 b

Gross profit margin (FY, 2017), %

93.2%

Net income (FY, 2017)

487.8 m

EBIT (FY, 2017)

528.8 m

Market capitalization (31-Oct-2017)

8.5 b

Closing share price (31-Oct-2017)

136.3

Cash (31-Dec-2017)

386 m

EV

8.2 b
Jazz Pharmaceuticals's current market capitalization is $8.5 b.
Annual
USDFY, 2016FY, 2017

Revenue

1.5 b1.6 b

Cost of goods sold

105.4 m110.2 m

Gross profit

1.4 b1.5 b

Gross profit Margin, %

93%93%
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

291.2 m306.6 m309.3 m333.7 m340.9 m336 m381.2 m374.2 m376.1 m

Cost of goods sold

30.7 m27 m28.3 m21.8 m28.4 m23.4 m24 m24.3 m25.1 m

Gross profit

260.5 m279.6 m281 m311.9 m312.5 m312.6 m357.2 m349.9 m351 m

Gross profit Margin, %

89%91%91%93%92%93%94%94%93%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

636.5 m684 m988.8 m366 m386 m

Accounts Receivable

Inventories

28.7 m30 m19.5 m34.1 m43.2 m

Current Assets

864.6 m1 b1.3 b748.1 m968.3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

268.3 m575 m782.6 m921.6 m998.9 m979.8 m868 m366.6 m347 m

Inventories

33.1 m37.6 m30.7 m30.8 m30 m25.4 m33.3 m32.4 m37.7 m

Current Assets

544.9 m878.5 m1.1 b1.2 b1.3 b1.3 b1.2 b744.2 m752.9 m

PP&E

38.5 m44.2 m71.3 m80.4 m83.5 m86.8 m93.5 m99.9 m119.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

216.3 m57.3 m329.5 m396.8 m487.8 m

Depreciation and Amortization

82.1 m133.7 m9.9 m11.8 m13.1 m

Inventories

(8.5 m)(7.6 m)6.3 m(17 m)(8.7 m)

Accounts Payable

5.1 m(38 m)(2.3 m)361 k214 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

43.6 m25.8 m70.7 m88.1 m88 m74.1 m111.3 m87.1 m86.5 m

Inventories

33.1 m37.6 m30.7 m30.8 m30 m25.4 m33.3 m32.4 m37.7 m

Accounts Payable

32.6 m29.7 m27.3 m26.4 m29.1 m32.6 m28.4 m17.6 m29.1 m
USDY, 2017

EV/EBIT

15.4 x

EV/CFO

11.8 x

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information